{"gene":"SFRP2","run_date":"2026-06-10T07:46:31","timeline":{"discoveries":[{"year":1998,"finding":"The cysteine-rich domain of sFRP-2 binds directly to Wnt-4, as demonstrated by co-immunoprecipitation, and sFRP-2 expression is induced downstream of Wnt-4 signaling in the developing metanephric kidney mesenchyme.","method":"Co-immunoprecipitation; in vivo expression analysis in Wnt-4 knockout mice; co-induction assay in isolated metanephric mesenchyme","journal":"Developmental dynamics","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — reciprocal binding demonstrated by Co-IP, combined with genetic (Wnt-4 KO) and co-induction experiments in a single rigorous study","pmids":["9853965"],"is_preprint":false},{"year":2000,"finding":"Sfrp-2 functions as a Wnt antagonist in vivo; injection of Sfrp-2 RNA into Xenopus embryos phenocopies Wnt antagonism, and Sfrp-2-expressing cells reduce the dermomyotome-inducing activity of Wnt1 and Wnt4 (but not Wnt3a) in somitic mesoderm explants.","method":"Xenopus embryo injection assay; chick somitic mesoderm explant culture with Sfrp2-expressing cells","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo functional assay in Xenopus replicated the antagonist activity, confirmed in chick explants with specificity for Wnt1/4 vs Wnt3a; two independent model systems","pmids":["10654605","10656762"],"is_preprint":false},{"year":2006,"finding":"Purified Sfrp-2 (and Sfrp-1) inhibits Wnt-3a-induced β-catenin accumulation in L cells, acting upstream of GSK-3 (as Sfrp-2 cannot inhibit LiCl-induced β-catenin accumulation), and Sfrp-2 inhibits ectopic Wnt-3a-stimulated proliferation in the chick neural tube.","method":"In vitro β-catenin accumulation assay with purified recombinant proteins; LiCl epistasis experiment; in ovo chick neural tube electroporation","journal":"Developmental dynamics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified proteins, epistasis experiment placing Sfrp2 upstream of GSK-3, and in vivo chick validation in one study","pmids":["16425220"],"is_preprint":false},{"year":2006,"finding":"Loss-of-function of both Sfrp1 and Sfrp2 in mice causes severe anteroposterior axis shortening and defective somite segmentation, with altered Notch signaling oscillations (abnormal Lfng and Hes7 expression); single knockouts show no phenotype, demonstrating functional redundancy.","method":"Double homozygous knockout mouse genetics; in situ hybridization for Notch pathway oscillation markers","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic loss-of-function with specific molecular readout (Notch oscillation markers), replicated across two papers with consistent redundancy finding","pmids":["16467359"],"is_preprint":false},{"year":2007,"finding":"Sfrp2 is the key paracrine factor secreted by Akt-modified mesenchymal stem cells that mediates myocardial survival after ischemic injury; treatment of cardiomyocytes with Sfrp2 increases cellular β-catenin and upregulates antiapoptotic gene expression.","method":"Functional genomic screen; recombinant protein treatment of cardiomyocytes; β-catenin measurement; antiapoptotic gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — functional genomic identification plus cell-based validation with β-catenin readout, single lab","pmids":["17251350"],"is_preprint":false},{"year":2007,"finding":"SFRP2 inhibits cardiomyogenic differentiation by interrupting a positive transcriptional autofeedback loop of Wnt3a: SFRP2 inhibits Wnt3a transcription (which is normally driven by canonical Wnt/TCF4 signaling), thereby preventing mesoderm specification.","method":"Gain- and loss-of-function (recombinant protein addition; Sfrp2 siRNA knockdown) in mouse embryonal carcinoma stem cells; Wnt3a transcription assay; canonical Wnt signaling reporter assay","journal":"Stem cells (Dayton, Ohio)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with specific molecular pathway placement (Wnt3a/TCF4 axis), single lab","pmids":["17916803"],"is_preprint":false},{"year":2008,"finding":"sFRP2 activates canonical Wnt/β-catenin signaling in intestinal epithelium via Frizzled receptors, stabilizing β-catenin, activating Wnt target genes, and enhancing cell proliferation; this activity is directly regulated by thyroid hormone receptor TRα1.","method":"In vitro and in vivo expression analysis; luciferase reporter assays; β-catenin stabilization assay; TR knockout mouse model; laser microdissection and transcriptional profiling","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays and KO mouse with functional readouts confirming agonist activity, single lab","pmids":["19001373"],"is_preprint":false},{"year":2008,"finding":"sFRP2 enhances mesenchymal stem cell engraftment and regenerative capacity; specific shRNA knockdown of sFRP2 in MRL-MSCs decreases proliferation and engraftment, while retroviral overexpression of sFRP2 in WT-MSCs recapitulates the enhanced regenerative phenotype in vivo.","method":"shRNA knockdown; retroviral overexpression; in vivo engraftment and granulation tissue assays; murine myocardial infarct model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function in vivo with defined cellular phenotype, single lab","pmids":["19017790"],"is_preprint":false},{"year":2008,"finding":"Inactivation of Sfrp2 in mice causes brachydactyly with decreased chondrocyte proliferation and delayed differentiation; Sfrp2 can repress canonical Wnt signaling by Wnt1, Wnt9a, and Wnt4 in vitro, and Sfrp2-/- mice show mild increases in β-catenin in phalangeal elements.","method":"Sfrp2 knockout mouse; in vitro Wnt signaling reporter assay; histological analysis; TOPGAL reporter mice","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined phenotype, in vitro functional assay, single lab","pmids":["18446812"],"is_preprint":false},{"year":2008,"finding":"Sfrp1 and Sfrp2 regulate trunk formation through both canonical Wnt/β-catenin (somitogenesis) and planar cell polarity (convergent extension) pathways; genetic epistasis with Dkk1-deficient and Loop-tail (PCP mutant) mice placed Sfrps as modulators of both pathways.","method":"Triple knockout mouse genetics; genetic epistasis with Dkk1 KO and Loop-tail (Vangl2) mutants","journal":"Genesis (New York, N.Y. : 2000)","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic epistasis in multiple mutant backgrounds definitively placing Sfrp1/2 in both Wnt pathways","pmids":["18257070"],"is_preprint":false},{"year":2008,"finding":"Sfrp2 suppresses UV-induced apoptosis in canine mammary tumor cells through NF-κB activation and JNK suppression; sFRP2 co-localizes with extracellular matrix, enhances FAK tyrosine phosphorylation, and activates NF-κB (demonstrated by EMSA) while suppressing JNK after UV treatment.","method":"sFRP2 overexpression; TUNEL and DNA fragmentation assays; immunofluorescence co-localization; immunoprecipitation; immunoblotting; EMSA","journal":"Breast cancer research and treatment","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple orthogonal methods (co-localization, IP, EMSA) in single lab establishing NF-κB/JNK mechanism","pmids":["16791480"],"is_preprint":false},{"year":2010,"finding":"Sfrp2 specifically inhibits mammalian BMP1 (procollagen C-proteinase) activity in vitro, thereby inhibiting procollagen I processing and collagen maturation; this inhibition is specific to Sfrp2 (not Sfrp1 or Sfrp3), and exogenous Sfrp2 reduces collagen deposition and fibrosis after myocardial infarction.","method":"In vitro fluorogenic peptide procollagen C-proteinase activity assay with recombinant proteins; in vitro procollagen processing assay; primary cardiac fibroblast culture; rat MI model with direct injection","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution with recombinant proteins, confirmed in primary cells, validated in vivo; replicated across multiple assays in one rigorous study","pmids":["21078975"],"is_preprint":false},{"year":2010,"finding":"sFRP2 inhibits both Wnt and BMP signaling in mesenchymal stem cells to promote self-renewal; sFRP2-mediated inhibition of BMP signaling (assessed by pSMAD 1/5/8 levels) is independent of its effects on the Wnt pathway, and this suppresses MSC lineage commitment and reduces ectopic calcification.","method":"sFRP2 overexpression; western blot for pSMAD 1/5/8; osteogenic/chondrogenic differentiation assays; in vivo MSC transplantation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — western blot pathway dissection with functional differentiation readouts, single lab","pmids":["20826809"],"is_preprint":false},{"year":2010,"finding":"sFRP2 augments canonical Wnt3a signaling in HEK293A cells, enhancing LRP6 phosphorylation, β-catenin cytosolic accumulation, nuclear translocation, and TCF-mediated transcription in a dose-dependent manner; this enhancement is abolished by DKK1.","method":"Recombinant sFRP2 addition to HEK293A cells; western blot for LRP6 phosphorylation and β-catenin; Top/Fop luciferase reporter assay; Wnt pathway qPCR arrays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro reconstitution with recombinant protein plus reporter assay and DKK1 epistasis, single lab","pmids":["20723538"],"is_preprint":false},{"year":2011,"finding":"SFRP2-induced angiogenesis (endothelial tube formation) requires NFATc3; shRNA silencing of NFATc3 in endothelial cells abolishes SFRP2-stimulated tube formation, placing SFRP2 upstream of calcineurin/NFAT signaling in angiogenesis.","method":"shRNA knockdown of NFATc3; endothelial tube formation assay; in vivo MMTV-neu transgenic mouse tumor model with tacrolimus treatment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown with specific signaling readout and in vivo validation, single lab","pmids":["21673995"],"is_preprint":false},{"year":2012,"finding":"sFRP1 and sFRP2 activate the Wnt/planar-cell-polarity/Rac1 pathway in dopamine neurons; compound sFRP1-/-;sFRP2-/- mice display a Wnt/PCP phenotype (anteroposterior VM shortening, lateral expansion of Shh domain) similar to Wnt5a-/- mice, and low/medium concentrations of sFRP1/2 promote dopaminergic differentiation mimicking Wnt5a.","method":"Double knockout mouse genetics; primary ventral midbrain culture; embryonic stem cell differentiation assay; Rac1 pathway activation assay","journal":"Stem cells (Dayton, Ohio)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with Wnt5a KO phenotype comparison, in vitro pathway activation assay, single lab","pmids":["22290867"],"is_preprint":false},{"year":2015,"finding":"Sfrp2 binds Wnt6 and inhibits Wnt6 canonical signaling in cardiac progenitor cells, which in turn activates the non-canonical Wnt/PCP pathway through JNK, inducing cardiac transcription factors and CPC differentiation.","method":"Sfrp2 treatment of cardiac progenitor cells; Wnt6 binding assay; canonical Wnt reporter assay; JNK activation assay; cardiac transcription factor expression; ischemia-reperfusion injury model","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — binding assay plus pathway activation measurements with functional differentiation readout, single lab","pmids":["26071893"],"is_preprint":false},{"year":2015,"finding":"sFRP2 upregulates tissue-nonspecific alkaline phosphatase (TNAP) expression and activity specifically in cardiac fibroblasts (not other cell types), promoting extracellular inorganic phosphate production; this induction requires protein synthesis (abolished by cycloheximide) and N-glycosylation (abolished by tunicamycin), and is not observed with sFRP4.","method":"Recombinant sFRP2 treatment of cardiac fibroblasts; TNAP activity biochemical assay; cycloheximide and tunicamycin treatment; in vivo sFRP2 blockade in hamster heart failure model","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro biochemical assay with mechanistic controls, confirmed in vivo, single lab","pmids":["25972450"],"is_preprint":false},{"year":2016,"finding":"sFRP2 from aged fibroblasts activates a signaling cascade in melanoma cells: sFRP2 decreases β-catenin and MITF, leading to loss of APE1 (a redox effector), which attenuates DNA damage response and confers resistance to vemurafenib; aged fibroblast sFRP2 also augments angiogenesis and metastasis.","method":"Recombinant sFRP2 treatment; shRNA knockdown; western blot for β-catenin, MITF, APE1; in vitro and in vivo metastasis assays; aged vs. young mouse models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods defining the β-catenin→MITF→APE1 cascade, validated in vivo, published in high-rigor journal","pmids":["27042933"],"is_preprint":false},{"year":2016,"finding":"SFRP2 augments WNT16B-initiated β-catenin signaling in cancer cells by enhancing WNT16B binding to Frizzled receptors FZD3/4/6 (coordinated by LRP6 co-receptor); SFRP2 transcription in fibroblasts after genotoxic treatment is primarily driven by the NF-κB complex.","method":"Co-treatment assays; Frizzled receptor binding experiments; LRP6 co-receptor assay; DKK1 inhibition; NF-κB inhibitor studies; neutralizing antibody co-treatment","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — receptor binding and co-receptor experiments with mechanistic dissection, single lab","pmids":["26751775"],"is_preprint":false},{"year":2016,"finding":"sFRP2 activates Wnt/β-catenin signaling in cardiac fibroblasts (increased Axin2, Wnt3a, nuclear β-catenin), promotes fibroblast proliferation coupled with anaerobic glycolysis (Warburg effect), and upregulates MMP1, MMP13, MMP2, and MMP9 activity leading to collagenolysis; these effects are specific to cardiac fibroblasts.","method":"Recombinant sFRP2 treatment; western blot for β-catenin; Axin2/Wnt3a expression; glucose/lactate measurement; MMP activity assays; collagen quantification; Wnt perturbation experiments","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (signaling, metabolic, enzymatic assays) in single lab establishing comprehensive mechanism","pmids":["27605451"],"is_preprint":false},{"year":2016,"finding":"sFRP2 functions as a melanogenic stimulator through β-catenin signaling, upregulating MITF and tyrosinase in melanocytes; this was demonstrated in primary human melanocytes using sFRP2 lentiviral overexpression and shRNA knockdown.","method":"Lentiviral sFRP2 overexpression; shRNA knockdown; melanogenesis assays; MITF and tyrosinase expression analysis; melanocyte-fibroblast co-culture; ex vivo skin culture","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with mechanistic pathway (β-catenin/MITF/tyrosinase) in primary human cells, single lab","pmids":["26763443"],"is_preprint":false},{"year":2016,"finding":"sFRP2 redirects non-canonical Wnt signaling from Frizzled 7 (Fz7) to Ror2 during Xenopus gastrulation; sFRP2 stabilizes Wnt5a-Ror2 complexes at the membrane promoting Ror2 signal transduction, while simultaneously inhibiting Fz7 signaling (likely by blocking Fz7 endocytosis); the cysteine-rich domain of sFRP2 is sufficient for Ror2 activation.","method":"Xenopus gastrulation assay; dominant-negative and overexpression constructs; membrane complex stabilization assay; CRD domain truncation experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mechanistic dissection of receptor switching with domain mapping and in vivo Xenopus validation, multiple orthogonal approaches in single study","pmids":["27129770"],"is_preprint":false},{"year":2018,"finding":"SFRP2 promotes osteosarcoma phenotypes (suppressed osteoblast differentiation, induction of FOXM1 and CYR61) through a β-catenin-independent mechanism; ectopic SFRP2 overexpression in normal osteoblast precursors is sufficient to induce OS phenotypes, and inhibition of SFRP2, FOXM1, or CYR61 represses tumorigenic potential.","method":"iPSC-derived osteoblast differentiation model; ectopic overexpression; shRNA knockdown; gene expression analysis; in vitro tumor phenotype assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with pathway placement (β-catenin-independent, FOXM1/CYR61), single lab","pmids":["30385632"],"is_preprint":false},{"year":2019,"finding":"LncRNA Safe stabilizes Sfrp2 mRNA through complementary binding at the 3'-end forming a Safe-Sfrp2 RNA duplex; the RNA-binding protein HuR binds this duplex and maintains stability of both RNAs; knockdown of HuR dramatically reduces Safe and Sfrp2 mRNA levels and inhibits TGF-β-induced cardiac fibrosis.","method":"Dual-luciferase assay; RNA electrophoretic mobility shift assay (EMSA); RNA immunoprecipitation (RIP); shRNA knockdown; cardiac fibroblast culture; MI mouse model","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal molecular methods (EMSA, RIP, reporter assay) plus in vivo validation establishing Safe-Sfrp2-HuR complex mechanism","pmids":["31695768"],"is_preprint":false},{"year":2019,"finding":"DRG neuron-derived sFRP2 activates NF-κB pathway in macrophages by destabilizing the β-catenin/p65 complex, promoting M1 polarization and macrophage migration; lentiviral knockdown of sFRP2 in L4/L5 DRG suppresses inflammatory cell infiltration in gouty arthritis.","method":"Lentiviral shRNA in vivo; immunoprecipitation (β-catenin/p65 complex); western blot; immunofluorescence; macrophage polarization assays; MSU-induced GA mouse model","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — immunoprecipitation establishing β-catenin/p65 complex, combined with in vivo lentiviral KD and functional assays, single lab","pmids":["31281508"],"is_preprint":false},{"year":2020,"finding":"Sfrp2 mediates interactions between indolent breast cancer cells and alveolar epithelial cells: signals from alveolar type 1 epithelial cells induce Sfrp2 in breast cancer cells, which promotes fibronectin fibril formation and integrin-dependent pro-survival signaling; Sfrp2 blockade reduces the burden of indolent disease.","method":"Combined in vivo RNA sequencing; drop-out CRISPR screen; in vivo metastasis model; Sfrp2 blocking experiments; fibronectin fibril formation assay","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide drop-out screen plus in vivo validation with specific functional readout (fibronectin fibril formation/integrin survival), replicated across multiple assays","pmids":["32094692"],"is_preprint":false},{"year":2021,"finding":"Sfrp2 deficiency reduces BMSC/SSC colony-forming efficiency, impairs trabecular bone formation in ectopic assay, and dramatically impairs cortical bone defect regeneration; Sfrp2-deficient BMSCs show reduced Lrp6 activation and reduced Wnt target gene expression (Axin2, c-myc, Cyclin D1); addition of recombinant Sfrp2 restores these activities, demonstrating Sfrp2 acts as a Wnt agonist in skeletal stem cells.","method":"Sfrp2 knockout mouse; ectopic bone formation assay; cortical bone defect model; colony-forming efficiency assay; western blot for Lrp6/Wnt targets; recombinant Sfrp2 rescue experiment; osteogenic differentiation assays","journal":"Bone research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with in vivo and in vitro phenotypes, pathway mechanistic analysis, and recombinant protein rescue confirming Wnt agonist activity; multiple orthogonal methods","pmids":["34857734"],"is_preprint":false},{"year":2021,"finding":"SFRP2 induces a mesenchymal glioblastoma subtype transition by suppressing SOX2 through a non-canonical Wnt/KLF4/PDGFR/phospho-AKT/SOX2 signaling axis; SFRP2 decreases tumor sphere formation and proliferation but increases cell motility, and conditioned media from SFRP2-overexpressing cells increases CD206 on macrophages.","method":"In vitro overexpression/knockdown; sphere formation assay; limiting dilution assay; phospho-AKT western blot; spatial gene expression analysis of human tumor tissue","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple functional assays with pathway dissection (non-canonical Wnt/KLF4/PDGFR/AKT), single lab","pmids":["34021259"],"is_preprint":false},{"year":2024,"finding":"TGF-β1 signaling in alveolar fibroblasts induces sFRP2 expression near AEC2s; sFRP2 then activates a Krt5+ basal cell program via Frizzled 5 (Fzd5) receptor, requiring downstream calcineurin signaling and nuclear NFATc3 accumulation for KRT5 expression (non-canonical Wnt pathway).","method":"AEC2-fibroblast coculture organoids; precision-cut lung slices; single-cell RNA-seq; EGCG TGF-β1 inhibitor treatment; Fzd5 and calcineurin pathway inhibition experiments; NFATc3 nuclear localization imaging","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mechanistic dissection using multiple orthogonal methods (organoids, PCLS, scRNA-seq, receptor/signaling inhibition) identifying Fzd5/calcineurin/NFATc3 axis, single lab but rigorous","pmids":["38980870"],"is_preprint":false},{"year":2025,"finding":"SFRP2 in CAFs regulates the abscopal effect of radioimmunotherapy; conditional Sfrp2 knockout in CAFs boosts the abscopal effect by rewiring the vascular-immune microenvironment to promote CD8+ T cell recruitment; PAI-1 secreted from irradiated tumors triggers pericyte-to-CAF transition into SFRP2high CAFs via the LRP1/p65 axis.","method":"In vivo genome-wide CRISPR screen; conditional CAF-specific Sfrp2 KO; in vivo lineage tracing; serum proteomics; LRP1/p65 signaling assays; humanized PDX models with SFRP2/PAI-1 pharmacological blockade","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide in vivo CRISPR screen, conditional KO, lineage tracing, and pharmacological validation in multiple model systems establishing PAI-1/LRP1/p65/SFRP2 axis","pmids":["40086438"],"is_preprint":false},{"year":2003,"finding":"The SFRP2 gene is a transcriptional target of the Pax2 transcription factor; Pax2 expression in embryonic kidney cells strongly activates Sfrp2 expression correlated with changes in chromatin structure at the Sfrp2 locus including regions of Pax2 binding.","method":"Pax2-expressing retroviral transformation of embryonic kidney cells; gene expression screen; chromatin structure analysis at Sfrp2 locus; transient transactivation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — chromatin structure analysis plus transactivation assay linking Pax2 binding to Sfrp2 expression, single lab","pmids":["14561758"],"is_preprint":false},{"year":2005,"finding":"Multiple myeloma cells constitutively secrete sFRP-2 (but not sFRP-1, sFRP-3, or DKK-1) and thereby suppress osteoblast differentiation induced by BMP-2; immunodepletion of sFRP-2 from conditioned medium significantly restores mineralized nodule formation, establishing sFRP-2 as the predominant mediator of impaired bone formation.","method":"ELISA/western blot protein detection in conditioned medium; alkaline phosphatase activity assay; in vitro mineralization assay; immunodepletion of sFRP-2","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — immunodepletion rescue experiment combined with protein-level detection and functional osteoblast assays establishing sFRP-2 as the causative factor, single lab with multiple orthogonal methods","pmids":["16030194"],"is_preprint":false},{"year":2016,"finding":"KDM2A, a histone demethylase, represses SFRP2 transcription by decreasing H3K4 and H3K36 methylation at the SFRP2 promoter; silencing KDM2A de-represses SFRP2 expression and promotes osteogenic/dentinogenic differentiation of dental stem cells via Osterix.","method":"ChIP assay for H3K4/H3K36 methylation at SFRP2 promoter; KDM2A siRNA knockdown; osteogenic differentiation assays; in vivo transplantation","journal":"Cell proliferation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP assay directly linking histone demethylation marks to SFRP2 promoter with functional differentiation readout, single lab","pmids":["27074224"],"is_preprint":false}],"current_model":"SFRP2 is a secreted protein with dual and context-dependent roles in Wnt signaling: it can act as a Wnt antagonist by binding Wnt ligands (via its cysteine-rich domain) and blocking receptor engagement, but can also potentiate canonical Wnt/β-catenin signaling (by augmenting LRP6 phosphorylation and β-catenin accumulation) and redirect non-canonical Wnt signaling from Fz7 to Ror2 by stabilizing Wnt5a–Ror2 complexes; beyond Wnt, SFRP2 directly inhibits BMP1/tolloid metalloproteinase activity to limit collagen maturation, upregulates TNAP in cardiac fibroblasts, activates calcineurin/NFATc3-dependent angiogenesis, modulates NF-κB and JNK in apoptosis, promotes fibronectin fibril formation and integrin survival signaling in disseminated cancer cells, and in the aged tumor microenvironment drives melanoma metastasis and therapy resistance through a β-catenin→MITF→APE1 cascade."},"narrative":{"mechanistic_narrative":"SFRP2 is a secreted cysteine-rich modulator of Wnt signaling that exerts opposite, strongly context-dependent effects on the pathway: it antagonizes Wnt by binding ligands such as Wnt-4, Wnt1, and Wnt6 through its cysteine-rich domain to block receptor engagement and β-catenin accumulation upstream of GSK-3 [PMID:9853965, PMID:10654605, PMID:10656762, PMID:16425220, PMID:26071893], yet it can also potentiate canonical Wnt/β-catenin signaling by augmenting LRP6 phosphorylation, β-catenin stabilization, and TCF-dependent transcription in a DKK1-sensitive manner [PMID:20723538, PMID:34857734]. In non-canonical signaling it redirects Wnt output by stabilizing Wnt5a–Ror2 complexes at the membrane while inhibiting Fz7, with the cysteine-rich domain sufficient for Ror2 activation [PMID:27129770], and it engages Fzd5–calcineurin–NFATc3 signaling to drive cell-fate programs [PMID:38980870]. Genetically, Sfrp1 and Sfrp2 act redundantly to control trunk and somite formation through both canonical Wnt and planar-cell-polarity pathways, with somite segmentation defects linked to disrupted Notch oscillations [PMID:16467359, PMID:18257070]. Beyond Wnt, SFRP2 directly inhibits the BMP1/procollagen C-proteinase to limit collagen maturation and fibrosis [PMID:21078975], suppresses BMP/SMAD signaling to maintain mesenchymal stem cell self-renewal [PMID:20826809], and in disease contexts—including aged-stroma melanoma metastasis via a β-catenin→MITF→APE1 cascade [PMID:27042933], indolent breast-cancer survival through fibronectin/integrin signaling [PMID:32094692], and CAF-driven tumor microenvironment remodeling [PMID:40086438]—acts as a paracrine effector secreted by stromal and stem-cell populations. SFRP2 expression is itself controlled at multiple levels, including Pax2 transactivation, NF-κB induction, KDM2A-mediated histone demethylation, and lncRNA Safe/HuR-dependent mRNA stabilization [PMID:26751775, PMID:31695768, PMID:14561758, PMID:27074224].","teleology":[{"year":1998,"claim":"Established the molecular basis for SFRP2's interaction with Wnt by showing its cysteine-rich domain directly binds a Wnt ligand, defining the structural module through which it modulates Wnt signaling.","evidence":"Co-immunoprecipitation and in vivo expression analysis in Wnt-4 knockout metanephric mesenchyme","pmids":["9853965"],"confidence":"High","gaps":["Did not establish whether binding is antagonistic or agonistic","Binding affinity and specificity across Wnt family untested"]},{"year":2000,"claim":"Defined SFRP2 as a bona fide in vivo Wnt antagonist with ligand specificity, answering whether ligand binding translates into functional pathway inhibition.","evidence":"Xenopus embryo RNA injection and chick somitic mesoderm explant assays showing inhibition of Wnt1/Wnt4 but not Wnt3a","pmids":["10654605","10656762"],"confidence":"High","gaps":["Mechanism of ligand selectivity unresolved","Did not address agonist contexts later observed"]},{"year":2006,"claim":"Placed SFRP2 antagonism upstream of GSK-3 and demonstrated genetic redundancy with SFRP1, clarifying where in the canonical cascade it acts and why single knockouts are silent.","evidence":"In vitro β-catenin accumulation with purified protein plus LiCl epistasis; double Sfrp1/Sfrp2 knockout mice with Notch oscillation readouts","pmids":["16425220","16467359"],"confidence":"High","gaps":["Did not resolve how Sfrp2 links to Notch oscillations mechanistically","Receptor-level mechanism not defined"]},{"year":2008,"claim":"Revealed the agonist face of SFRP2—stabilizing β-catenin and activating Wnt targets via Frizzled—overturning a purely antagonistic model and tying it to thyroid hormone control and developmental phenotypes.","evidence":"Reporter and β-catenin stabilization assays, TR knockout and Sfrp2 knockout mice (brachydactyly), and PCP/canonical epistasis in triple knockouts","pmids":["19001373","18446812","18257070"],"confidence":"High","gaps":["Molecular determinant switching antagonist vs agonist behavior unknown","Direct receptor-binding mode in agonist context not shown"]},{"year":2010,"claim":"Identified BMP1/procollagen C-proteinase as a direct, Wnt-independent enzymatic target of SFRP2, expanding its mechanism to direct protease inhibition controlling collagen maturation.","evidence":"In vitro fluorogenic procollagen C-proteinase assay with recombinant proteins, primary cardiac fibroblasts, and rat MI model","pmids":["21078975"],"confidence":"High","gaps":["Structural basis of BMP1 inhibition undefined","Selectivity over related tolloid proteases not fully mapped"]},{"year":2010,"claim":"Showed SFRP2 augments canonical Wnt3a signaling at the receptor level and independently suppresses BMP/SMAD signaling, mechanistically separating its dual modulatory activities.","evidence":"Recombinant protein addition with LRP6 phosphorylation/β-catenin western blots, DKK1 epistasis, and pSMAD1/5/8 analysis in MSCs","pmids":["20723538","20826809"],"confidence":"Medium","gaps":["Single-lab biochemistry","How a Wnt antagonist enhances LRP6 phosphorylation not reconciled"]},{"year":2011,"claim":"Connected SFRP2 to calcineurin/NFAT signaling in angiogenesis, establishing a non-Wnt transcriptional effector pathway.","evidence":"shRNA silencing of NFATc3 abolishing SFRP2-driven endothelial tube formation; in vivo MMTV-neu tumor model with tacrolimus","pmids":["21673995"],"confidence":"Medium","gaps":["Receptor coupling SFRP2 to calcineurin not identified here","Single lab"]},{"year":2016,"claim":"Resolved how SFRP2 redirects rather than simply blocks non-canonical Wnt, defining a receptor-switching mechanism from Fz7 to Ror2 via Wnt5a-Ror2 complex stabilization.","evidence":"Xenopus gastrulation assays, dominant-negative constructs, membrane complex stabilization, and CRD truncation mapping","pmids":["27129770"],"confidence":"High","gaps":["Structural detail of complex stabilization unresolved","Generality beyond gastrulation untested"]},{"year":2016,"claim":"Defined SFRP2's role in the aged tumor microenvironment, establishing a β-catenin→MITF→APE1 cascade driving melanoma metastasis and therapy resistance.","evidence":"Recombinant protein and shRNA with β-catenin/MITF/APE1 westerns and aged vs young in vivo metastasis models","pmids":["27042933"],"confidence":"High","gaps":["Receptor mediating the aged-fibroblast SFRP2 signal not defined","Reconciliation with melanogenic β-catenin/MITF activation in melanocytes [#21] unresolved"]},{"year":2016,"claim":"Catalogued SFRP2's context-specific outputs in cardiac fibroblasts and cancer—Warburg metabolism with MMP-driven collagenolysis, WNT16B/FZD potentiation, and NF-κB-driven transcriptional induction.","evidence":"Recombinant protein treatment with metabolic, MMP, and signaling assays; Frizzled/LRP6 binding and NF-κB inhibitor studies","pmids":["27605451","26751775","26763443"],"confidence":"Medium","gaps":["Single-lab mechanistic dissections","Cell-type specificity determinants unexplained"]},{"year":2015,"claim":"Showed SFRP2 upregulates TNAP and ectopic phosphate production specifically in cardiac fibroblasts in a protein-synthesis- and glycosylation-dependent manner, indicating a transcriptional/biosynthetic downstream program.","evidence":"Recombinant sFRP2 with TNAP activity assays, cycloheximide/tunicamycin controls, and hamster heart failure blockade","pmids":["25972450"],"confidence":"Medium","gaps":["Signaling pathway linking SFRP2 to TNAP induction unidentified","Single lab"]},{"year":2018,"claim":"Demonstrated β-catenin-independent oncogenic SFRP2 signaling through FOXM1/CYR61 in osteosarcoma and through KLF4/PDGFR/AKT/SOX2 in glioblastoma, broadening its mechanistic repertoire beyond Wnt/β-catenin.","evidence":"iPSC-derived osteoblast and GBM overexpression/knockdown models with gene-expression and phospho-AKT analysis","pmids":["30385632","34021259"],"confidence":"Medium","gaps":["Receptors mediating β-catenin-independent effects unknown","Single-lab models"]},{"year":2020,"claim":"Established SFRP2 as a pro-survival paracrine effector in disseminated cancer, promoting fibronectin fibril formation and integrin signaling that sustains indolent disease.","evidence":"In vivo RNA-seq, dropout CRISPR screen, metastasis models, and Sfrp2 blockade with fibronectin fibril assays","pmids":["32094692"],"confidence":"High","gaps":["Molecular link between SFRP2 and fibronectin assembly undefined","Receptor not identified"]},{"year":2021,"claim":"Confirmed SFRP2 acts as a Wnt agonist in skeletal stem cells via LRP6 activation, with knockout impairing bone regeneration and recombinant protein rescuing it, reinforcing the agonist mechanism with genetic and rescue evidence.","evidence":"Sfrp2 knockout mice, ectopic and cortical bone defect assays, Lrp6/Wnt-target westerns, and recombinant rescue","pmids":["34857734"],"confidence":"High","gaps":["Direct LRP6 binding not shown","Determinants of agonist vs antagonist outcome still unresolved"]},{"year":2024,"claim":"Defined a TGF-β1→fibroblast SFRP2→Fzd5/calcineurin/NFATc3 axis activating Krt5+ basal cell programs, linking SFRP2 to non-canonical NFAT signaling in lung remodeling.","evidence":"AEC2-fibroblast organoids, precision-cut lung slices, scRNA-seq, and Fzd5/calcineurin inhibition with NFATc3 imaging","pmids":["38980870"],"confidence":"High","gaps":["Whether the same Fzd5/NFAT axis operates in other SFRP2 contexts untested"]},{"year":2019,"claim":"Identified upstream regulators of SFRP2 abundance, including lncRNA Safe/HuR-mediated mRNA stabilization and DRG-neuron-derived SFRP2 driving macrophage NF-κB/M1 polarization via β-catenin/p65 destabilization.","evidence":"EMSA/RIP/reporter assays for Safe-Sfrp2-HuR duplex; immunoprecipitation of β-catenin/p65 with in vivo lentiviral knockdown","pmids":["31695768","31281508"],"confidence":"Medium","gaps":["Generalizability of Safe/HuR regulation across tissues unknown","β-catenin/p65 mechanism shown in single lab"]},{"year":2025,"claim":"Placed SFRP2 within tumor stroma plasticity, showing PAI-1/LRP1/p65-driven pericyte-to-CAF conversion generates SFRP2-high CAFs that suppress anti-tumor immunity, with knockout enhancing radioimmunotherapy.","evidence":"In vivo genome-wide CRISPR screen, conditional CAF Sfrp2 knockout, lineage tracing, and pharmacological SFRP2/PAI-1 blockade in PDX models","pmids":["40086438"],"confidence":"High","gaps":["Direct SFRP2 effector on T cells/vasculature not fully resolved","Receptor mediating immunosuppression unknown"]},{"year":null,"claim":"The molecular determinant that switches SFRP2 between Wnt antagonist and agonist, and between canonical and non-canonical/β-catenin-independent outputs, remains undefined across cell contexts.","evidence":"No single study reconciles the opposing receptor-level mechanisms","pmids":[],"confidence":"Low","gaps":["No structural model of context-dependent receptor selection","Concentration- and co-receptor-dependence not unified","No comprehensive receptor-interaction map"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,13,22,27]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,22]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[11]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[11,26,32]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[10,26]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,13,22,29]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,8,9,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[18,26,30]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[11,20,26]}],"complexes":[],"partners":["WNT4","WNT6","WNT5A","ROR2","FZD5","LRP6","BMP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96HF1","full_name":"Secreted frizzled-related protein 2","aliases":["Secreted apoptosis-related protein 1","SARP-1"],"length_aa":295,"mass_kda":33.5,"function":"Soluble frizzled-related proteins (sFRPS) function as modulators of Wnt signaling through direct interaction with Wnts. They have a role in regulating cell growth and differentiation in specific cell types. SFRP2 may be important for eye retinal development and for myogenesis","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q96HF1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SFRP2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SFRP2","total_profiled":1310},"omim":[{"mim_id":"619257","title":"HR UPSTREAM OPEN READING FRAME; HRURF","url":"https://www.omim.org/entry/619257"},{"mim_id":"606570","title":"SECRETED FRIZZLED-RELATED PROTEIN 4; SFRP4","url":"https://www.omim.org/entry/606570"},{"mim_id":"605083","title":"FRIZZLED-RELATED PROTEIN; FRZB","url":"https://www.omim.org/entry/605083"},{"mim_id":"604158","title":"SECRETED FRIZZLED-RELATED PROTEIN 5; SFRP5","url":"https://www.omim.org/entry/604158"},{"mim_id":"604157","title":"SECRETED FRIZZLED-RELATED PROTEIN 2; SFRP2","url":"https://www.omim.org/entry/604157"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Intermediate filaments","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":342.0},{"tissue":"gallbladder","ntpm":298.7},{"tissue":"urinary bladder","ntpm":287.2}],"url":"https://www.proteinatlas.org/search/SFRP2"},"hgnc":{"alias_symbol":["SARP1","SDF-5","FRP-2"],"prev_symbol":[]},"alphafold":{"accession":"Q96HF1","domains":[{"cath_id":"1.10.2000.10","chopping":"39-143","consensus_level":"high","plddt":93.5955,"start":39,"end":143},{"cath_id":"2.40.50.120","chopping":"172-291","consensus_level":"high","plddt":83.7928,"start":172,"end":291}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96HF1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96HF1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96HF1-F1-predicted_aligned_error_v6.png","plddt_mean":82.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SFRP2","jax_strain_url":"https://www.jax.org/strain/search?query=SFRP2"},"sequence":{"accession":"Q96HF1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96HF1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96HF1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96HF1"}},"corpus_meta":[{"pmid":"17251350","id":"PMC_17251350","title":"Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17251350","citation_count":416,"is_preprint":false},{"pmid":"27042933","id":"PMC_27042933","title":"sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/27042933","citation_count":329,"is_preprint":false},{"pmid":"29080679","id":"PMC_29080679","title":"SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/29080679","citation_count":278,"is_preprint":false},{"pmid":"16030194","id":"PMC_16030194","title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16030194","citation_count":262,"is_preprint":false},{"pmid":"34282151","id":"PMC_34282151","title":"Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34282151","citation_count":218,"is_preprint":false},{"pmid":"21078975","id":"PMC_21078975","title":"Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21078975","citation_count":183,"is_preprint":false},{"pmid":"10656762","id":"PMC_10656762","title":"Cloning and expression of the Wnt antagonists Sfrp-2 and Frzb during chick development.","date":"2000","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10656762","citation_count":138,"is_preprint":false},{"pmid":"19017790","id":"PMC_19017790","title":"The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19017790","citation_count":136,"is_preprint":false},{"pmid":"16467359","id":"PMC_16467359","title":"Sfrp1 and Sfrp2 regulate anteroposterior axis elongation and somite segmentation during mouse embryogenesis.","date":"2006","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16467359","citation_count":122,"is_preprint":false},{"pmid":"19095296","id":"PMC_19095296","title":"SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway.","date":"2008","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19095296","citation_count":122,"is_preprint":false},{"pmid":"29361151","id":"PMC_29361151","title":"Chemoprevention of colorectal cancer by black raspberry anthocyanins involved the modulation of gut microbiota and SFRP2 demethylation.","date":"2018","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/29361151","citation_count":113,"is_preprint":false},{"pmid":"17848950","id":"PMC_17848950","title":"Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer.","date":"2007","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17848950","citation_count":111,"is_preprint":false},{"pmid":"34790288","id":"PMC_34790288","title":"SFRP2 Improves Mitochondrial Dynamics and Mitochondrial Biogenesis, Oxidative Stress, and Apoptosis in Diabetic Cardiomyopathy.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/34790288","citation_count":110,"is_preprint":false},{"pmid":"18257070","id":"PMC_18257070","title":"Sfrp1, Sfrp2, and Sfrp5 regulate the Wnt/beta-catenin and the planar cell polarity pathways during early trunk formation in mouse.","date":"2008","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/18257070","citation_count":108,"is_preprint":false},{"pmid":"9853965","id":"PMC_9853965","title":"sFRP-2 is a target of the Wnt-4 signaling pathway in the developing metanephric kidney.","date":"1998","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/9853965","citation_count":108,"is_preprint":false},{"pmid":"16425220","id":"PMC_16425220","title":"Differential inhibition of Wnt-3a by Sfrp-1, Sfrp-2, and Sfrp-3.","date":"2006","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/16425220","citation_count":107,"is_preprint":false},{"pmid":"11222670","id":"PMC_11222670","title":"Pax-6 regulates expression of SFRP-2 and Wnt-7b in the developing CNS.","date":"2001","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11222670","citation_count":106,"is_preprint":false},{"pmid":"19001373","id":"PMC_19001373","title":"The frizzled-related sFRP2 gene is a target of thyroid hormone receptor alpha1 and activates beta-catenin signaling in mouse intestine.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19001373","citation_count":105,"is_preprint":false},{"pmid":"20826809","id":"PMC_20826809","title":"sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20826809","citation_count":102,"is_preprint":false},{"pmid":"26751775","id":"PMC_26751775","title":"SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26751775","citation_count":100,"is_preprint":false},{"pmid":"28753106","id":"PMC_28753106","title":"Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples.","date":"2017","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/28753106","citation_count":96,"is_preprint":false},{"pmid":"18203283","id":"PMC_18203283","title":"Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening.","date":"2008","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18203283","citation_count":95,"is_preprint":false},{"pmid":"10654605","id":"PMC_10654605","title":"SHH-N upregulates Sfrp2 to mediate its competitive interaction with WNT1 and WNT4 in the somitic mesoderm.","date":"2000","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10654605","citation_count":93,"is_preprint":false},{"pmid":"32094692","id":"PMC_32094692","title":"Crosstalk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination.","date":"2020","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32094692","citation_count":92,"is_preprint":false},{"pmid":"31182988","id":"PMC_31182988","title":"Exosomes Derived from TIMP2-Modified Human Umbilical Cord Mesenchymal Stem Cells Enhance the Repair Effect in Rat Model with Myocardial Infarction Possibly by the Akt/Sfrp2 Pathway.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/31182988","citation_count":92,"is_preprint":false},{"pmid":"27605451","id":"PMC_27605451","title":"sFRP2 activates Wnt/β-catenin signaling in cardiac fibroblasts: differential roles in cell growth, energy metabolism, and extracellular matrix remodeling.","date":"2016","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27605451","citation_count":85,"is_preprint":false},{"pmid":"31695768","id":"PMC_31695768","title":"LncRNA-Safe contributes to cardiac fibrosis through Safe-Sfrp2-HuR complex in mouse myocardial infarction.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31695768","citation_count":81,"is_preprint":false},{"pmid":"28851501","id":"PMC_28851501","title":"TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.","date":"2017","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28851501","citation_count":80,"is_preprint":false},{"pmid":"21673995","id":"PMC_21673995","title":"The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21673995","citation_count":77,"is_preprint":false},{"pmid":"25452142","id":"PMC_25452142","title":"Exendin-4 protects adipose-derived mesenchymal stem cells from apoptosis induced by hydrogen peroxide through the PI3K/Akt-Sfrp2 pathways.","date":"2014","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25452142","citation_count":75,"is_preprint":false},{"pmid":"18990230","id":"PMC_18990230","title":"Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.","date":"2008","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18990230","citation_count":74,"is_preprint":false},{"pmid":"19100252","id":"PMC_19100252","title":"Sfrp1 and Sfrp2 are required for normal male sexual development in mice.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19100252","citation_count":74,"is_preprint":false},{"pmid":"38980870","id":"PMC_38980870","title":"A fibroblast-dependent TGF-β1/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38980870","citation_count":69,"is_preprint":false},{"pmid":"17212358","id":"PMC_17212358","title":"VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17212358","citation_count":69,"is_preprint":false},{"pmid":"17410438","id":"PMC_17410438","title":"Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.","date":"2007","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17410438","citation_count":69,"is_preprint":false},{"pmid":"21571909","id":"PMC_21571909","title":"Genistein attenuates WNT signaling by up-regulating sFRP2 in a human colon cancer cell line.","date":"2011","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/21571909","citation_count":66,"is_preprint":false},{"pmid":"20723538","id":"PMC_20723538","title":"Secreted Frizzled-related protein-2 (sFRP2) augments canonical Wnt3a-induced signaling.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20723538","citation_count":63,"is_preprint":false},{"pmid":"17639423","id":"PMC_17639423","title":"SFRP2 methylation in fecal DNA--a marker for colorectal polyps.","date":"2007","source":"International journal of colorectal disease","url":"https://pubmed.ncbi.nlm.nih.gov/17639423","citation_count":58,"is_preprint":false},{"pmid":"18446812","id":"PMC_18446812","title":"Brachy-syndactyly caused by loss of Sfrp2 function.","date":"2008","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18446812","citation_count":58,"is_preprint":false},{"pmid":"17916803","id":"PMC_17916803","title":"SFRP2 regulates cardiomyogenic differentiation by inhibiting a positive transcriptional autofeedback loop of Wnt3a.","date":"2007","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/17916803","citation_count":56,"is_preprint":false},{"pmid":"25759530","id":"PMC_25759530","title":"Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas.","date":"2015","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25759530","citation_count":56,"is_preprint":false},{"pmid":"26763443","id":"PMC_26763443","title":"Secreted Frizzled-Related Protein 2 (sFRP2) Functions as a Melanogenic Stimulator; the Role of sFRP2 in UV-Induced Hyperpigmentary Disorders.","date":"2016","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26763443","citation_count":55,"is_preprint":false},{"pmid":"21033217","id":"PMC_21033217","title":"Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients.","date":"2010","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21033217","citation_count":55,"is_preprint":false},{"pmid":"22290867","id":"PMC_22290867","title":"SFRP1 and SFRP2 dose-dependently regulate midbrain dopamine neuron development in vivo and in embryonic stem cells.","date":"2012","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/22290867","citation_count":53,"is_preprint":false},{"pmid":"25202404","id":"PMC_25202404","title":"DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA.","date":"2014","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/25202404","citation_count":53,"is_preprint":false},{"pmid":"26337424","id":"PMC_26337424","title":"Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.","date":"2015","source":"Journal of applied genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26337424","citation_count":50,"is_preprint":false},{"pmid":"11025221","id":"PMC_11025221","title":"Sfrp-1 and sfrp-2 are expressed in overlapping and distinct domains during chick development.","date":"2000","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11025221","citation_count":50,"is_preprint":false},{"pmid":"32071544","id":"PMC_32071544","title":"Multiple Roles of sFRP2 in Cardiac Development and Cardiovascular Disease.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32071544","citation_count":49,"is_preprint":false},{"pmid":"30385632","id":"PMC_30385632","title":"Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30385632","citation_count":48,"is_preprint":false},{"pmid":"30953362","id":"PMC_30953362","title":"miR-218-5p regulates skin and hair follicle development through Wnt/β-catenin signaling pathway by targeting SFRP2.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30953362","citation_count":47,"is_preprint":false},{"pmid":"27074224","id":"PMC_27074224","title":"Demethylation of SFRP2 by histone demethylase KDM2A regulated osteo-/dentinogenic differentiation of stem cells of the apical papilla.","date":"2016","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/27074224","citation_count":47,"is_preprint":false},{"pmid":"14999144","id":"PMC_14999144","title":"Secreted frizzled-related protein 2 (SFRP2) is highly expressed in canine mammary gland tumors but not in normal mammary glands.","date":"2004","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/14999144","citation_count":47,"is_preprint":false},{"pmid":"16791480","id":"PMC_16791480","title":"Secreted frizzled related protein 2 (sFRP2) decreases susceptibility to UV-induced apoptosis in primary culture of canine mammary gland tumors by NF-kappaB activation or JNK suppression.","date":"2006","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/16791480","citation_count":45,"is_preprint":false},{"pmid":"20448436","id":"PMC_20448436","title":"The advantages and disadvantages of sfrp1 and sfrp2 expression in pathological events.","date":"2010","source":"The Tohoku journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20448436","citation_count":43,"is_preprint":false},{"pmid":"18322704","id":"PMC_18322704","title":"Inhibition of myoblast differentiation by Sfrp1 and Sfrp2.","date":"2008","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/18322704","citation_count":43,"is_preprint":false},{"pmid":"11574152","id":"PMC_11574152","title":"Characterization of Spiroplasma citri adhesion related protein SARP1, which contains a domain of a novel family designated sarpin.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11574152","citation_count":42,"is_preprint":false},{"pmid":"27821163","id":"PMC_27821163","title":"Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential.","date":"2016","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27821163","citation_count":40,"is_preprint":false},{"pmid":"28794794","id":"PMC_28794794","title":"SFRP2 enhances the osteogenic differentiation of apical papilla stem cells by antagonizing the canonical WNT pathway.","date":"2017","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28794794","citation_count":40,"is_preprint":false},{"pmid":"27659069","id":"PMC_27659069","title":"Methylation of SFRP2 gene as a promising noninvasive biomarker using feces in colorectal cancer diagnosis: a systematic meta-analysis.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27659069","citation_count":39,"is_preprint":false},{"pmid":"24464051","id":"PMC_24464051","title":"Downregulation of sFRP-2 by epigenetic silencing activates the β-catenin/Wnt signaling pathway in esophageal basaloid squamous cell carcinoma.","date":"2014","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24464051","citation_count":35,"is_preprint":false},{"pmid":"22634081","id":"PMC_22634081","title":"Label-free LC-MSMS analysis of vitreous from autoimmune uveitis reveals a significant decrease in secreted Wnt signalling inhibitors DKK3 and SFRP2.","date":"2012","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/22634081","citation_count":35,"is_preprint":false},{"pmid":"35364458","id":"PMC_35364458","title":"HNRNPA2B1 inhibited SFRP2 and activated Wnt-β/catenin via m6A-mediated miR-106b-5p processing to aggravate stemness in lung adenocarcinoma.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/35364458","citation_count":33,"is_preprint":false},{"pmid":"27129770","id":"PMC_27129770","title":"Secreted Frizzled-related Protein 2 (sFRP2) Redirects Non-canonical Wnt Signaling from Fz7 to Ror2 during Vertebrate Gastrulation.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27129770","citation_count":33,"is_preprint":false},{"pmid":"18466761","id":"PMC_18466761","title":"The anti-apoptotic effect of IGF-1 on tissue resident stem cells is mediated via PI3-kinase dependent secreted frizzled related protein 2 (Sfrp2) release.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18466761","citation_count":33,"is_preprint":false},{"pmid":"29142517","id":"PMC_29142517","title":"Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population?","date":"2017","source":"Intestinal research","url":"https://pubmed.ncbi.nlm.nih.gov/29142517","citation_count":33,"is_preprint":false},{"pmid":"19362047","id":"PMC_19362047","title":"Secreted frizzled related protein (sFRP)-2 inhibits bone formation and promotes cell proliferation in ameloblastoma.","date":"2009","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19362047","citation_count":32,"is_preprint":false},{"pmid":"16407498","id":"PMC_16407498","title":"WNT pathways in the neonatal ovine uterus: potential specification of endometrial gland morphogenesis by SFRP2.","date":"2006","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/16407498","citation_count":32,"is_preprint":false},{"pmid":"26071893","id":"PMC_26071893","title":"Inhibition of Wnt6 by Sfrp2 regulates adult cardiac progenitor cell differentiation by differential modulation of Wnt pathways.","date":"2015","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26071893","citation_count":32,"is_preprint":false},{"pmid":"27540971","id":"PMC_27540971","title":"KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.","date":"2016","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/27540971","citation_count":32,"is_preprint":false},{"pmid":"30075814","id":"PMC_30075814","title":"TET1 exerts its anti-tumor functions via demethylating DACT2 and SFRP2 to antagonize Wnt/β-catenin signaling pathway in nasopharyngeal carcinoma cells.","date":"2018","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/30075814","citation_count":31,"is_preprint":false},{"pmid":"33097493","id":"PMC_33097493","title":"sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33097493","citation_count":31,"is_preprint":false},{"pmid":"14561758","id":"PMC_14561758","title":"The secreted frizzled related protein 2 (SFRP2) gene is a target of the Pax2 transcription factor.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14561758","citation_count":30,"is_preprint":false},{"pmid":"29620167","id":"PMC_29620167","title":"Decreased expression of SFRP2 promotes development of the pituitary corticotroph adenoma by upregulating Wnt signaling.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29620167","citation_count":29,"is_preprint":false},{"pmid":"31281508","id":"PMC_31281508","title":"Nerve modulation therapy in gouty arthritis: targeting increased sFRP2 expression in dorsal root ganglion regulates macrophage polarization and alleviates endothelial damage.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31281508","citation_count":29,"is_preprint":false},{"pmid":"30852954","id":"PMC_30852954","title":"Performance of a MethyLight assay for methylated SFRP2 DNA detection in colorectal cancer tissue and serum.","date":"2019","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/30852954","citation_count":29,"is_preprint":false},{"pmid":"25202403","id":"PMC_25202403","title":"Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.","date":"2014","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/25202403","citation_count":29,"is_preprint":false},{"pmid":"27685706","id":"PMC_27685706","title":"SFRP2 Is Associated with Increased Adiposity and VEGF Expression.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27685706","citation_count":28,"is_preprint":false},{"pmid":"26960688","id":"PMC_26960688","title":"miR-522 contributes to cell proliferation of hepatocellular carcinoma by targeting DKK1 and SFRP2.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26960688","citation_count":28,"is_preprint":false},{"pmid":"36327957","id":"PMC_36327957","title":"m6A Methyltransferase METTL3 Reduces Hippocampal Neuron Apoptosis in a Mouse Model of Autism Through the MALAT1/SFRP2/Wnt/β-catenin Axis.","date":"2022","source":"Psychiatry investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36327957","citation_count":28,"is_preprint":false},{"pmid":"28244619","id":"PMC_28244619","title":"SFRP2 enhanced the adipogenic and neuronal differentiation potentials of stem cells from apical papilla.","date":"2017","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/28244619","citation_count":26,"is_preprint":false},{"pmid":"25972450","id":"PMC_25972450","title":"Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts.","date":"2015","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25972450","citation_count":26,"is_preprint":false},{"pmid":"21709714","id":"PMC_21709714","title":"Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis.","date":"2011","source":"Acta medica Okayama","url":"https://pubmed.ncbi.nlm.nih.gov/21709714","citation_count":26,"is_preprint":false},{"pmid":"19778523","id":"PMC_19778523","title":"Wnt modulators, SFRP-1, and SFRP-2 are expressed in osteoblasts and differentially regulate hematopoietic stem cells.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19778523","citation_count":25,"is_preprint":false},{"pmid":"31430541","id":"PMC_31430541","title":"sFRP2 promotes airway inflammation and Th17/Treg imbalance in COPD via Wnt/β-catenin pathway.","date":"2019","source":"Respiratory physiology & neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31430541","citation_count":24,"is_preprint":false},{"pmid":"34852024","id":"PMC_34852024","title":"Downregulation of SFRP2 facilitates cancer stemness and radioresistance of glioma cells via activating Wnt/β-catenin signaling.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34852024","citation_count":24,"is_preprint":false},{"pmid":"30345838","id":"PMC_30345838","title":"DNA hypermethylation of SFRP2 influences the pathology of rheumatoid arthritis through the canonical Wnt signaling in model rats.","date":"2018","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/30345838","citation_count":24,"is_preprint":false},{"pmid":"36002889","id":"PMC_36002889","title":"Identification of novel early pancreatic cancer biomarkers KIF5B and SFRP2 from \"first contact\" interactions in the tumor microenvironment.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/36002889","citation_count":24,"is_preprint":false},{"pmid":"40086438","id":"PMC_40086438","title":"PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy.","date":"2025","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/40086438","citation_count":23,"is_preprint":false},{"pmid":"24648690","id":"PMC_24648690","title":"Expression of sfrp2 is increased in catagen of hair follicles and inhibits keratinocyte proliferation.","date":"2014","source":"Annals of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/24648690","citation_count":23,"is_preprint":false},{"pmid":"29462326","id":"PMC_29462326","title":"Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis.","date":"2018","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29462326","citation_count":23,"is_preprint":false},{"pmid":"31469431","id":"PMC_31469431","title":"SFRP2 promotes stem cells from apical papilla-mediated periodontal tissue regeneration in miniature pig.","date":"2019","source":"Journal of oral rehabilitation","url":"https://pubmed.ncbi.nlm.nih.gov/31469431","citation_count":23,"is_preprint":false},{"pmid":"34857734","id":"PMC_34857734","title":"Secreted frizzled related-protein 2 (Sfrp2) deficiency decreases adult skeletal stem cell function in mice.","date":"2021","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/34857734","citation_count":22,"is_preprint":false},{"pmid":"34021259","id":"PMC_34021259","title":"SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34021259","citation_count":22,"is_preprint":false},{"pmid":"30576962","id":"PMC_30576962","title":"Methylation status of SFRP1, SFRP2, RASSF1A, RARβ and DAPK1 genes in patients with oral squamous cell carcinoma.","date":"2018","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/30576962","citation_count":21,"is_preprint":false},{"pmid":"22136354","id":"PMC_22136354","title":"Alterations in promoter methylation status of tumor suppressor HIC1, SFRP2, and DAPK1 genes in prostate carcinomas.","date":"2011","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22136354","citation_count":21,"is_preprint":false},{"pmid":"37106069","id":"PMC_37106069","title":"METTL3 promotes the malignancy of non-small cell lung cancer by N6-methyladenosine modifying SFRP2.","date":"2023","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37106069","citation_count":20,"is_preprint":false},{"pmid":"33854626","id":"PMC_33854626","title":"Methylated SFRP2 and SDC2 in stool specimens for Colorectal Cancer early detection: A cost-effective strategy for Chinese population.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33854626","citation_count":20,"is_preprint":false},{"pmid":"35019227","id":"PMC_35019227","title":"Langerhans cells and SFRP2/Wnt/beta-catenin signalling control adaptation of skin epidermis to mechanical stretching.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35019227","citation_count":19,"is_preprint":false},{"pmid":"24140542","id":"PMC_24140542","title":"Sfrp1 and Sfrp2 are not involved in Wnt/β-catenin signal silencing during lens induction but are required for maintenance of Wnt/β-catenin signaling in lens epithelial cells.","date":"2013","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/24140542","citation_count":19,"is_preprint":false},{"pmid":"25802696","id":"PMC_25802696","title":"Study of SFRP1 and SFRP2 methylation status in patients with de novo Acute Myeloblastic Leukemia.","date":"2015","source":"International journal of hematology-oncology and stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25802696","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54247,"output_tokens":8991,"usd":0.148803,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18951,"output_tokens":5516,"usd":0.116328,"stage2_stop_reason":"end_turn"},"total_usd":0.265131,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"The cysteine-rich domain of sFRP-2 binds directly to Wnt-4, as demonstrated by co-immunoprecipitation, and sFRP-2 expression is induced downstream of Wnt-4 signaling in the developing metanephric kidney mesenchyme.\",\n      \"method\": \"Co-immunoprecipitation; in vivo expression analysis in Wnt-4 knockout mice; co-induction assay in isolated metanephric mesenchyme\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reciprocal binding demonstrated by Co-IP, combined with genetic (Wnt-4 KO) and co-induction experiments in a single rigorous study\",\n      \"pmids\": [\"9853965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Sfrp-2 functions as a Wnt antagonist in vivo; injection of Sfrp-2 RNA into Xenopus embryos phenocopies Wnt antagonism, and Sfrp-2-expressing cells reduce the dermomyotome-inducing activity of Wnt1 and Wnt4 (but not Wnt3a) in somitic mesoderm explants.\",\n      \"method\": \"Xenopus embryo injection assay; chick somitic mesoderm explant culture with Sfrp2-expressing cells\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo functional assay in Xenopus replicated the antagonist activity, confirmed in chick explants with specificity for Wnt1/4 vs Wnt3a; two independent model systems\",\n      \"pmids\": [\"10654605\", \"10656762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Purified Sfrp-2 (and Sfrp-1) inhibits Wnt-3a-induced β-catenin accumulation in L cells, acting upstream of GSK-3 (as Sfrp-2 cannot inhibit LiCl-induced β-catenin accumulation), and Sfrp-2 inhibits ectopic Wnt-3a-stimulated proliferation in the chick neural tube.\",\n      \"method\": \"In vitro β-catenin accumulation assay with purified recombinant proteins; LiCl epistasis experiment; in ovo chick neural tube electroporation\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified proteins, epistasis experiment placing Sfrp2 upstream of GSK-3, and in vivo chick validation in one study\",\n      \"pmids\": [\"16425220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Loss-of-function of both Sfrp1 and Sfrp2 in mice causes severe anteroposterior axis shortening and defective somite segmentation, with altered Notch signaling oscillations (abnormal Lfng and Hes7 expression); single knockouts show no phenotype, demonstrating functional redundancy.\",\n      \"method\": \"Double homozygous knockout mouse genetics; in situ hybridization for Notch pathway oscillation markers\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic loss-of-function with specific molecular readout (Notch oscillation markers), replicated across two papers with consistent redundancy finding\",\n      \"pmids\": [\"16467359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Sfrp2 is the key paracrine factor secreted by Akt-modified mesenchymal stem cells that mediates myocardial survival after ischemic injury; treatment of cardiomyocytes with Sfrp2 increases cellular β-catenin and upregulates antiapoptotic gene expression.\",\n      \"method\": \"Functional genomic screen; recombinant protein treatment of cardiomyocytes; β-catenin measurement; antiapoptotic gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — functional genomic identification plus cell-based validation with β-catenin readout, single lab\",\n      \"pmids\": [\"17251350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SFRP2 inhibits cardiomyogenic differentiation by interrupting a positive transcriptional autofeedback loop of Wnt3a: SFRP2 inhibits Wnt3a transcription (which is normally driven by canonical Wnt/TCF4 signaling), thereby preventing mesoderm specification.\",\n      \"method\": \"Gain- and loss-of-function (recombinant protein addition; Sfrp2 siRNA knockdown) in mouse embryonal carcinoma stem cells; Wnt3a transcription assay; canonical Wnt signaling reporter assay\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with specific molecular pathway placement (Wnt3a/TCF4 axis), single lab\",\n      \"pmids\": [\"17916803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"sFRP2 activates canonical Wnt/β-catenin signaling in intestinal epithelium via Frizzled receptors, stabilizing β-catenin, activating Wnt target genes, and enhancing cell proliferation; this activity is directly regulated by thyroid hormone receptor TRα1.\",\n      \"method\": \"In vitro and in vivo expression analysis; luciferase reporter assays; β-catenin stabilization assay; TR knockout mouse model; laser microdissection and transcriptional profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays and KO mouse with functional readouts confirming agonist activity, single lab\",\n      \"pmids\": [\"19001373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"sFRP2 enhances mesenchymal stem cell engraftment and regenerative capacity; specific shRNA knockdown of sFRP2 in MRL-MSCs decreases proliferation and engraftment, while retroviral overexpression of sFRP2 in WT-MSCs recapitulates the enhanced regenerative phenotype in vivo.\",\n      \"method\": \"shRNA knockdown; retroviral overexpression; in vivo engraftment and granulation tissue assays; murine myocardial infarct model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function in vivo with defined cellular phenotype, single lab\",\n      \"pmids\": [\"19017790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Inactivation of Sfrp2 in mice causes brachydactyly with decreased chondrocyte proliferation and delayed differentiation; Sfrp2 can repress canonical Wnt signaling by Wnt1, Wnt9a, and Wnt4 in vitro, and Sfrp2-/- mice show mild increases in β-catenin in phalangeal elements.\",\n      \"method\": \"Sfrp2 knockout mouse; in vitro Wnt signaling reporter assay; histological analysis; TOPGAL reporter mice\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined phenotype, in vitro functional assay, single lab\",\n      \"pmids\": [\"18446812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Sfrp1 and Sfrp2 regulate trunk formation through both canonical Wnt/β-catenin (somitogenesis) and planar cell polarity (convergent extension) pathways; genetic epistasis with Dkk1-deficient and Loop-tail (PCP mutant) mice placed Sfrps as modulators of both pathways.\",\n      \"method\": \"Triple knockout mouse genetics; genetic epistasis with Dkk1 KO and Loop-tail (Vangl2) mutants\",\n      \"journal\": \"Genesis (New York, N.Y. : 2000)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic epistasis in multiple mutant backgrounds definitively placing Sfrp1/2 in both Wnt pathways\",\n      \"pmids\": [\"18257070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Sfrp2 suppresses UV-induced apoptosis in canine mammary tumor cells through NF-κB activation and JNK suppression; sFRP2 co-localizes with extracellular matrix, enhances FAK tyrosine phosphorylation, and activates NF-κB (demonstrated by EMSA) while suppressing JNK after UV treatment.\",\n      \"method\": \"sFRP2 overexpression; TUNEL and DNA fragmentation assays; immunofluorescence co-localization; immunoprecipitation; immunoblotting; EMSA\",\n      \"journal\": \"Breast cancer research and treatment\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple orthogonal methods (co-localization, IP, EMSA) in single lab establishing NF-κB/JNK mechanism\",\n      \"pmids\": [\"16791480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Sfrp2 specifically inhibits mammalian BMP1 (procollagen C-proteinase) activity in vitro, thereby inhibiting procollagen I processing and collagen maturation; this inhibition is specific to Sfrp2 (not Sfrp1 or Sfrp3), and exogenous Sfrp2 reduces collagen deposition and fibrosis after myocardial infarction.\",\n      \"method\": \"In vitro fluorogenic peptide procollagen C-proteinase activity assay with recombinant proteins; in vitro procollagen processing assay; primary cardiac fibroblast culture; rat MI model with direct injection\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution with recombinant proteins, confirmed in primary cells, validated in vivo; replicated across multiple assays in one rigorous study\",\n      \"pmids\": [\"21078975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"sFRP2 inhibits both Wnt and BMP signaling in mesenchymal stem cells to promote self-renewal; sFRP2-mediated inhibition of BMP signaling (assessed by pSMAD 1/5/8 levels) is independent of its effects on the Wnt pathway, and this suppresses MSC lineage commitment and reduces ectopic calcification.\",\n      \"method\": \"sFRP2 overexpression; western blot for pSMAD 1/5/8; osteogenic/chondrogenic differentiation assays; in vivo MSC transplantation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — western blot pathway dissection with functional differentiation readouts, single lab\",\n      \"pmids\": [\"20826809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"sFRP2 augments canonical Wnt3a signaling in HEK293A cells, enhancing LRP6 phosphorylation, β-catenin cytosolic accumulation, nuclear translocation, and TCF-mediated transcription in a dose-dependent manner; this enhancement is abolished by DKK1.\",\n      \"method\": \"Recombinant sFRP2 addition to HEK293A cells; western blot for LRP6 phosphorylation and β-catenin; Top/Fop luciferase reporter assay; Wnt pathway qPCR arrays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro reconstitution with recombinant protein plus reporter assay and DKK1 epistasis, single lab\",\n      \"pmids\": [\"20723538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SFRP2-induced angiogenesis (endothelial tube formation) requires NFATc3; shRNA silencing of NFATc3 in endothelial cells abolishes SFRP2-stimulated tube formation, placing SFRP2 upstream of calcineurin/NFAT signaling in angiogenesis.\",\n      \"method\": \"shRNA knockdown of NFATc3; endothelial tube formation assay; in vivo MMTV-neu transgenic mouse tumor model with tacrolimus treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown with specific signaling readout and in vivo validation, single lab\",\n      \"pmids\": [\"21673995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"sFRP1 and sFRP2 activate the Wnt/planar-cell-polarity/Rac1 pathway in dopamine neurons; compound sFRP1-/-;sFRP2-/- mice display a Wnt/PCP phenotype (anteroposterior VM shortening, lateral expansion of Shh domain) similar to Wnt5a-/- mice, and low/medium concentrations of sFRP1/2 promote dopaminergic differentiation mimicking Wnt5a.\",\n      \"method\": \"Double knockout mouse genetics; primary ventral midbrain culture; embryonic stem cell differentiation assay; Rac1 pathway activation assay\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with Wnt5a KO phenotype comparison, in vitro pathway activation assay, single lab\",\n      \"pmids\": [\"22290867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Sfrp2 binds Wnt6 and inhibits Wnt6 canonical signaling in cardiac progenitor cells, which in turn activates the non-canonical Wnt/PCP pathway through JNK, inducing cardiac transcription factors and CPC differentiation.\",\n      \"method\": \"Sfrp2 treatment of cardiac progenitor cells; Wnt6 binding assay; canonical Wnt reporter assay; JNK activation assay; cardiac transcription factor expression; ischemia-reperfusion injury model\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — binding assay plus pathway activation measurements with functional differentiation readout, single lab\",\n      \"pmids\": [\"26071893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"sFRP2 upregulates tissue-nonspecific alkaline phosphatase (TNAP) expression and activity specifically in cardiac fibroblasts (not other cell types), promoting extracellular inorganic phosphate production; this induction requires protein synthesis (abolished by cycloheximide) and N-glycosylation (abolished by tunicamycin), and is not observed with sFRP4.\",\n      \"method\": \"Recombinant sFRP2 treatment of cardiac fibroblasts; TNAP activity biochemical assay; cycloheximide and tunicamycin treatment; in vivo sFRP2 blockade in hamster heart failure model\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro biochemical assay with mechanistic controls, confirmed in vivo, single lab\",\n      \"pmids\": [\"25972450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"sFRP2 from aged fibroblasts activates a signaling cascade in melanoma cells: sFRP2 decreases β-catenin and MITF, leading to loss of APE1 (a redox effector), which attenuates DNA damage response and confers resistance to vemurafenib; aged fibroblast sFRP2 also augments angiogenesis and metastasis.\",\n      \"method\": \"Recombinant sFRP2 treatment; shRNA knockdown; western blot for β-catenin, MITF, APE1; in vitro and in vivo metastasis assays; aged vs. young mouse models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods defining the β-catenin→MITF→APE1 cascade, validated in vivo, published in high-rigor journal\",\n      \"pmids\": [\"27042933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SFRP2 augments WNT16B-initiated β-catenin signaling in cancer cells by enhancing WNT16B binding to Frizzled receptors FZD3/4/6 (coordinated by LRP6 co-receptor); SFRP2 transcription in fibroblasts after genotoxic treatment is primarily driven by the NF-κB complex.\",\n      \"method\": \"Co-treatment assays; Frizzled receptor binding experiments; LRP6 co-receptor assay; DKK1 inhibition; NF-κB inhibitor studies; neutralizing antibody co-treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — receptor binding and co-receptor experiments with mechanistic dissection, single lab\",\n      \"pmids\": [\"26751775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"sFRP2 activates Wnt/β-catenin signaling in cardiac fibroblasts (increased Axin2, Wnt3a, nuclear β-catenin), promotes fibroblast proliferation coupled with anaerobic glycolysis (Warburg effect), and upregulates MMP1, MMP13, MMP2, and MMP9 activity leading to collagenolysis; these effects are specific to cardiac fibroblasts.\",\n      \"method\": \"Recombinant sFRP2 treatment; western blot for β-catenin; Axin2/Wnt3a expression; glucose/lactate measurement; MMP activity assays; collagen quantification; Wnt perturbation experiments\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (signaling, metabolic, enzymatic assays) in single lab establishing comprehensive mechanism\",\n      \"pmids\": [\"27605451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"sFRP2 functions as a melanogenic stimulator through β-catenin signaling, upregulating MITF and tyrosinase in melanocytes; this was demonstrated in primary human melanocytes using sFRP2 lentiviral overexpression and shRNA knockdown.\",\n      \"method\": \"Lentiviral sFRP2 overexpression; shRNA knockdown; melanogenesis assays; MITF and tyrosinase expression analysis; melanocyte-fibroblast co-culture; ex vivo skin culture\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with mechanistic pathway (β-catenin/MITF/tyrosinase) in primary human cells, single lab\",\n      \"pmids\": [\"26763443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"sFRP2 redirects non-canonical Wnt signaling from Frizzled 7 (Fz7) to Ror2 during Xenopus gastrulation; sFRP2 stabilizes Wnt5a-Ror2 complexes at the membrane promoting Ror2 signal transduction, while simultaneously inhibiting Fz7 signaling (likely by blocking Fz7 endocytosis); the cysteine-rich domain of sFRP2 is sufficient for Ror2 activation.\",\n      \"method\": \"Xenopus gastrulation assay; dominant-negative and overexpression constructs; membrane complex stabilization assay; CRD domain truncation experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mechanistic dissection of receptor switching with domain mapping and in vivo Xenopus validation, multiple orthogonal approaches in single study\",\n      \"pmids\": [\"27129770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SFRP2 promotes osteosarcoma phenotypes (suppressed osteoblast differentiation, induction of FOXM1 and CYR61) through a β-catenin-independent mechanism; ectopic SFRP2 overexpression in normal osteoblast precursors is sufficient to induce OS phenotypes, and inhibition of SFRP2, FOXM1, or CYR61 represses tumorigenic potential.\",\n      \"method\": \"iPSC-derived osteoblast differentiation model; ectopic overexpression; shRNA knockdown; gene expression analysis; in vitro tumor phenotype assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with pathway placement (β-catenin-independent, FOXM1/CYR61), single lab\",\n      \"pmids\": [\"30385632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LncRNA Safe stabilizes Sfrp2 mRNA through complementary binding at the 3'-end forming a Safe-Sfrp2 RNA duplex; the RNA-binding protein HuR binds this duplex and maintains stability of both RNAs; knockdown of HuR dramatically reduces Safe and Sfrp2 mRNA levels and inhibits TGF-β-induced cardiac fibrosis.\",\n      \"method\": \"Dual-luciferase assay; RNA electrophoretic mobility shift assay (EMSA); RNA immunoprecipitation (RIP); shRNA knockdown; cardiac fibroblast culture; MI mouse model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal molecular methods (EMSA, RIP, reporter assay) plus in vivo validation establishing Safe-Sfrp2-HuR complex mechanism\",\n      \"pmids\": [\"31695768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DRG neuron-derived sFRP2 activates NF-κB pathway in macrophages by destabilizing the β-catenin/p65 complex, promoting M1 polarization and macrophage migration; lentiviral knockdown of sFRP2 in L4/L5 DRG suppresses inflammatory cell infiltration in gouty arthritis.\",\n      \"method\": \"Lentiviral shRNA in vivo; immunoprecipitation (β-catenin/p65 complex); western blot; immunofluorescence; macrophage polarization assays; MSU-induced GA mouse model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — immunoprecipitation establishing β-catenin/p65 complex, combined with in vivo lentiviral KD and functional assays, single lab\",\n      \"pmids\": [\"31281508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Sfrp2 mediates interactions between indolent breast cancer cells and alveolar epithelial cells: signals from alveolar type 1 epithelial cells induce Sfrp2 in breast cancer cells, which promotes fibronectin fibril formation and integrin-dependent pro-survival signaling; Sfrp2 blockade reduces the burden of indolent disease.\",\n      \"method\": \"Combined in vivo RNA sequencing; drop-out CRISPR screen; in vivo metastasis model; Sfrp2 blocking experiments; fibronectin fibril formation assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide drop-out screen plus in vivo validation with specific functional readout (fibronectin fibril formation/integrin survival), replicated across multiple assays\",\n      \"pmids\": [\"32094692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Sfrp2 deficiency reduces BMSC/SSC colony-forming efficiency, impairs trabecular bone formation in ectopic assay, and dramatically impairs cortical bone defect regeneration; Sfrp2-deficient BMSCs show reduced Lrp6 activation and reduced Wnt target gene expression (Axin2, c-myc, Cyclin D1); addition of recombinant Sfrp2 restores these activities, demonstrating Sfrp2 acts as a Wnt agonist in skeletal stem cells.\",\n      \"method\": \"Sfrp2 knockout mouse; ectopic bone formation assay; cortical bone defect model; colony-forming efficiency assay; western blot for Lrp6/Wnt targets; recombinant Sfrp2 rescue experiment; osteogenic differentiation assays\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with in vivo and in vitro phenotypes, pathway mechanistic analysis, and recombinant protein rescue confirming Wnt agonist activity; multiple orthogonal methods\",\n      \"pmids\": [\"34857734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SFRP2 induces a mesenchymal glioblastoma subtype transition by suppressing SOX2 through a non-canonical Wnt/KLF4/PDGFR/phospho-AKT/SOX2 signaling axis; SFRP2 decreases tumor sphere formation and proliferation but increases cell motility, and conditioned media from SFRP2-overexpressing cells increases CD206 on macrophages.\",\n      \"method\": \"In vitro overexpression/knockdown; sphere formation assay; limiting dilution assay; phospho-AKT western blot; spatial gene expression analysis of human tumor tissue\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple functional assays with pathway dissection (non-canonical Wnt/KLF4/PDGFR/AKT), single lab\",\n      \"pmids\": [\"34021259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TGF-β1 signaling in alveolar fibroblasts induces sFRP2 expression near AEC2s; sFRP2 then activates a Krt5+ basal cell program via Frizzled 5 (Fzd5) receptor, requiring downstream calcineurin signaling and nuclear NFATc3 accumulation for KRT5 expression (non-canonical Wnt pathway).\",\n      \"method\": \"AEC2-fibroblast coculture organoids; precision-cut lung slices; single-cell RNA-seq; EGCG TGF-β1 inhibitor treatment; Fzd5 and calcineurin pathway inhibition experiments; NFATc3 nuclear localization imaging\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mechanistic dissection using multiple orthogonal methods (organoids, PCLS, scRNA-seq, receptor/signaling inhibition) identifying Fzd5/calcineurin/NFATc3 axis, single lab but rigorous\",\n      \"pmids\": [\"38980870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SFRP2 in CAFs regulates the abscopal effect of radioimmunotherapy; conditional Sfrp2 knockout in CAFs boosts the abscopal effect by rewiring the vascular-immune microenvironment to promote CD8+ T cell recruitment; PAI-1 secreted from irradiated tumors triggers pericyte-to-CAF transition into SFRP2high CAFs via the LRP1/p65 axis.\",\n      \"method\": \"In vivo genome-wide CRISPR screen; conditional CAF-specific Sfrp2 KO; in vivo lineage tracing; serum proteomics; LRP1/p65 signaling assays; humanized PDX models with SFRP2/PAI-1 pharmacological blockade\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide in vivo CRISPR screen, conditional KO, lineage tracing, and pharmacological validation in multiple model systems establishing PAI-1/LRP1/p65/SFRP2 axis\",\n      \"pmids\": [\"40086438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The SFRP2 gene is a transcriptional target of the Pax2 transcription factor; Pax2 expression in embryonic kidney cells strongly activates Sfrp2 expression correlated with changes in chromatin structure at the Sfrp2 locus including regions of Pax2 binding.\",\n      \"method\": \"Pax2-expressing retroviral transformation of embryonic kidney cells; gene expression screen; chromatin structure analysis at Sfrp2 locus; transient transactivation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — chromatin structure analysis plus transactivation assay linking Pax2 binding to Sfrp2 expression, single lab\",\n      \"pmids\": [\"14561758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Multiple myeloma cells constitutively secrete sFRP-2 (but not sFRP-1, sFRP-3, or DKK-1) and thereby suppress osteoblast differentiation induced by BMP-2; immunodepletion of sFRP-2 from conditioned medium significantly restores mineralized nodule formation, establishing sFRP-2 as the predominant mediator of impaired bone formation.\",\n      \"method\": \"ELISA/western blot protein detection in conditioned medium; alkaline phosphatase activity assay; in vitro mineralization assay; immunodepletion of sFRP-2\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — immunodepletion rescue experiment combined with protein-level detection and functional osteoblast assays establishing sFRP-2 as the causative factor, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16030194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"KDM2A, a histone demethylase, represses SFRP2 transcription by decreasing H3K4 and H3K36 methylation at the SFRP2 promoter; silencing KDM2A de-represses SFRP2 expression and promotes osteogenic/dentinogenic differentiation of dental stem cells via Osterix.\",\n      \"method\": \"ChIP assay for H3K4/H3K36 methylation at SFRP2 promoter; KDM2A siRNA knockdown; osteogenic differentiation assays; in vivo transplantation\",\n      \"journal\": \"Cell proliferation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP assay directly linking histone demethylation marks to SFRP2 promoter with functional differentiation readout, single lab\",\n      \"pmids\": [\"27074224\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SFRP2 is a secreted protein with dual and context-dependent roles in Wnt signaling: it can act as a Wnt antagonist by binding Wnt ligands (via its cysteine-rich domain) and blocking receptor engagement, but can also potentiate canonical Wnt/β-catenin signaling (by augmenting LRP6 phosphorylation and β-catenin accumulation) and redirect non-canonical Wnt signaling from Fz7 to Ror2 by stabilizing Wnt5a–Ror2 complexes; beyond Wnt, SFRP2 directly inhibits BMP1/tolloid metalloproteinase activity to limit collagen maturation, upregulates TNAP in cardiac fibroblasts, activates calcineurin/NFATc3-dependent angiogenesis, modulates NF-κB and JNK in apoptosis, promotes fibronectin fibril formation and integrin survival signaling in disseminated cancer cells, and in the aged tumor microenvironment drives melanoma metastasis and therapy resistance through a β-catenin→MITF→APE1 cascade.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SFRP2 is a secreted cysteine-rich modulator of Wnt signaling that exerts opposite, strongly context-dependent effects on the pathway: it antagonizes Wnt by binding ligands such as Wnt-4, Wnt1, and Wnt6 through its cysteine-rich domain to block receptor engagement and β-catenin accumulation upstream of GSK-3 [#0, #1, #2, #16], yet it can also potentiate canonical Wnt/β-catenin signaling by augmenting LRP6 phosphorylation, β-catenin stabilization, and TCF-dependent transcription in a DKK1-sensitive manner [#13, #27]. In non-canonical signaling it redirects Wnt output by stabilizing Wnt5a–Ror2 complexes at the membrane while inhibiting Fz7, with the cysteine-rich domain sufficient for Ror2 activation [#22], and it engages Fzd5–calcineurin–NFATc3 signaling to drive cell-fate programs [#29]. Genetically, Sfrp1 and Sfrp2 act redundantly to control trunk and somite formation through both canonical Wnt and planar-cell-polarity pathways, with somite segmentation defects linked to disrupted Notch oscillations [#3, #9]. Beyond Wnt, SFRP2 directly inhibits the BMP1/procollagen C-proteinase to limit collagen maturation and fibrosis [#11], suppresses BMP/SMAD signaling to maintain mesenchymal stem cell self-renewal [#12], and in disease contexts—including aged-stroma melanoma metastasis via a β-catenin→MITF→APE1 cascade [#18], indolent breast-cancer survival through fibronectin/integrin signaling [#26], and CAF-driven tumor microenvironment remodeling [#30]—acts as a paracrine effector secreted by stromal and stem-cell populations. SFRP2 expression is itself controlled at multiple levels, including Pax2 transactivation, NF-κB induction, KDM2A-mediated histone demethylation, and lncRNA Safe/HuR-dependent mRNA stabilization [#19, #24, #31, #33].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established the molecular basis for SFRP2's interaction with Wnt by showing its cysteine-rich domain directly binds a Wnt ligand, defining the structural module through which it modulates Wnt signaling.\",\n      \"evidence\": \"Co-immunoprecipitation and in vivo expression analysis in Wnt-4 knockout metanephric mesenchyme\",\n      \"pmids\": [\"9853965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether binding is antagonistic or agonistic\", \"Binding affinity and specificity across Wnt family untested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined SFRP2 as a bona fide in vivo Wnt antagonist with ligand specificity, answering whether ligand binding translates into functional pathway inhibition.\",\n      \"evidence\": \"Xenopus embryo RNA injection and chick somitic mesoderm explant assays showing inhibition of Wnt1/Wnt4 but not Wnt3a\",\n      \"pmids\": [\"10654605\", \"10656762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ligand selectivity unresolved\", \"Did not address agonist contexts later observed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed SFRP2 antagonism upstream of GSK-3 and demonstrated genetic redundancy with SFRP1, clarifying where in the canonical cascade it acts and why single knockouts are silent.\",\n      \"evidence\": \"In vitro β-catenin accumulation with purified protein plus LiCl epistasis; double Sfrp1/Sfrp2 knockout mice with Notch oscillation readouts\",\n      \"pmids\": [\"16425220\", \"16467359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how Sfrp2 links to Notch oscillations mechanistically\", \"Receptor-level mechanism not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed the agonist face of SFRP2—stabilizing β-catenin and activating Wnt targets via Frizzled—overturning a purely antagonistic model and tying it to thyroid hormone control and developmental phenotypes.\",\n      \"evidence\": \"Reporter and β-catenin stabilization assays, TR knockout and Sfrp2 knockout mice (brachydactyly), and PCP/canonical epistasis in triple knockouts\",\n      \"pmids\": [\"19001373\", \"18446812\", \"18257070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular determinant switching antagonist vs agonist behavior unknown\", \"Direct receptor-binding mode in agonist context not shown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified BMP1/procollagen C-proteinase as a direct, Wnt-independent enzymatic target of SFRP2, expanding its mechanism to direct protease inhibition controlling collagen maturation.\",\n      \"evidence\": \"In vitro fluorogenic procollagen C-proteinase assay with recombinant proteins, primary cardiac fibroblasts, and rat MI model\",\n      \"pmids\": [\"21078975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of BMP1 inhibition undefined\", \"Selectivity over related tolloid proteases not fully mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed SFRP2 augments canonical Wnt3a signaling at the receptor level and independently suppresses BMP/SMAD signaling, mechanistically separating its dual modulatory activities.\",\n      \"evidence\": \"Recombinant protein addition with LRP6 phosphorylation/β-catenin western blots, DKK1 epistasis, and pSMAD1/5/8 analysis in MSCs\",\n      \"pmids\": [\"20723538\", \"20826809\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab biochemistry\", \"How a Wnt antagonist enhances LRP6 phosphorylation not reconciled\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected SFRP2 to calcineurin/NFAT signaling in angiogenesis, establishing a non-Wnt transcriptional effector pathway.\",\n      \"evidence\": \"shRNA silencing of NFATc3 abolishing SFRP2-driven endothelial tube formation; in vivo MMTV-neu tumor model with tacrolimus\",\n      \"pmids\": [\"21673995\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor coupling SFRP2 to calcineurin not identified here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved how SFRP2 redirects rather than simply blocks non-canonical Wnt, defining a receptor-switching mechanism from Fz7 to Ror2 via Wnt5a-Ror2 complex stabilization.\",\n      \"evidence\": \"Xenopus gastrulation assays, dominant-negative constructs, membrane complex stabilization, and CRD truncation mapping\",\n      \"pmids\": [\"27129770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of complex stabilization unresolved\", \"Generality beyond gastrulation untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined SFRP2's role in the aged tumor microenvironment, establishing a β-catenin→MITF→APE1 cascade driving melanoma metastasis and therapy resistance.\",\n      \"evidence\": \"Recombinant protein and shRNA with β-catenin/MITF/APE1 westerns and aged vs young in vivo metastasis models\",\n      \"pmids\": [\"27042933\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating the aged-fibroblast SFRP2 signal not defined\", \"Reconciliation with melanogenic β-catenin/MITF activation in melanocytes [#21] unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Catalogued SFRP2's context-specific outputs in cardiac fibroblasts and cancer—Warburg metabolism with MMP-driven collagenolysis, WNT16B/FZD potentiation, and NF-κB-driven transcriptional induction.\",\n      \"evidence\": \"Recombinant protein treatment with metabolic, MMP, and signaling assays; Frizzled/LRP6 binding and NF-κB inhibitor studies\",\n      \"pmids\": [\"27605451\", \"26751775\", \"26763443\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab mechanistic dissections\", \"Cell-type specificity determinants unexplained\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed SFRP2 upregulates TNAP and ectopic phosphate production specifically in cardiac fibroblasts in a protein-synthesis- and glycosylation-dependent manner, indicating a transcriptional/biosynthetic downstream program.\",\n      \"evidence\": \"Recombinant sFRP2 with TNAP activity assays, cycloheximide/tunicamycin controls, and hamster heart failure blockade\",\n      \"pmids\": [\"25972450\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway linking SFRP2 to TNAP induction unidentified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated β-catenin-independent oncogenic SFRP2 signaling through FOXM1/CYR61 in osteosarcoma and through KLF4/PDGFR/AKT/SOX2 in glioblastoma, broadening its mechanistic repertoire beyond Wnt/β-catenin.\",\n      \"evidence\": \"iPSC-derived osteoblast and GBM overexpression/knockdown models with gene-expression and phospho-AKT analysis\",\n      \"pmids\": [\"30385632\", \"34021259\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptors mediating β-catenin-independent effects unknown\", \"Single-lab models\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established SFRP2 as a pro-survival paracrine effector in disseminated cancer, promoting fibronectin fibril formation and integrin signaling that sustains indolent disease.\",\n      \"evidence\": \"In vivo RNA-seq, dropout CRISPR screen, metastasis models, and Sfrp2 blockade with fibronectin fibril assays\",\n      \"pmids\": [\"32094692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between SFRP2 and fibronectin assembly undefined\", \"Receptor not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Confirmed SFRP2 acts as a Wnt agonist in skeletal stem cells via LRP6 activation, with knockout impairing bone regeneration and recombinant protein rescuing it, reinforcing the agonist mechanism with genetic and rescue evidence.\",\n      \"evidence\": \"Sfrp2 knockout mice, ectopic and cortical bone defect assays, Lrp6/Wnt-target westerns, and recombinant rescue\",\n      \"pmids\": [\"34857734\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct LRP6 binding not shown\", \"Determinants of agonist vs antagonist outcome still unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a TGF-β1→fibroblast SFRP2→Fzd5/calcineurin/NFATc3 axis activating Krt5+ basal cell programs, linking SFRP2 to non-canonical NFAT signaling in lung remodeling.\",\n      \"evidence\": \"AEC2-fibroblast organoids, precision-cut lung slices, scRNA-seq, and Fzd5/calcineurin inhibition with NFATc3 imaging\",\n      \"pmids\": [\"38980870\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same Fzd5/NFAT axis operates in other SFRP2 contexts untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified upstream regulators of SFRP2 abundance, including lncRNA Safe/HuR-mediated mRNA stabilization and DRG-neuron-derived SFRP2 driving macrophage NF-κB/M1 polarization via β-catenin/p65 destabilization.\",\n      \"evidence\": \"EMSA/RIP/reporter assays for Safe-Sfrp2-HuR duplex; immunoprecipitation of β-catenin/p65 with in vivo lentiviral knockdown\",\n      \"pmids\": [\"31695768\", \"31281508\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generalizability of Safe/HuR regulation across tissues unknown\", \"β-catenin/p65 mechanism shown in single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placed SFRP2 within tumor stroma plasticity, showing PAI-1/LRP1/p65-driven pericyte-to-CAF conversion generates SFRP2-high CAFs that suppress anti-tumor immunity, with knockout enhancing radioimmunotherapy.\",\n      \"evidence\": \"In vivo genome-wide CRISPR screen, conditional CAF Sfrp2 knockout, lineage tracing, and pharmacological SFRP2/PAI-1 blockade in PDX models\",\n      \"pmids\": [\"40086438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SFRP2 effector on T cells/vasculature not fully resolved\", \"Receptor mediating immunosuppression unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular determinant that switches SFRP2 between Wnt antagonist and agonist, and between canonical and non-canonical/β-catenin-independent outputs, remains undefined across cell contexts.\",\n      \"evidence\": \"No single study reconciles the opposing receptor-level mechanisms\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of context-dependent receptor selection\", \"Concentration- and co-receptor-dependence not unified\", \"No comprehensive receptor-interaction map\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 13, 22, 27]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 22]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [11, 26, 32]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [10, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 13, 22, 29]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 8, 9, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [18, 26, 30]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [11, 20, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"WNT4\", \"WNT6\", \"WNT5A\", \"ROR2\", \"FZD5\", \"LRP6\", \"BMP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}